Ανακοινώσεις  
Call for Proposals: "Call for proposals to support awareness raising and information campaigns on the risks of irregular migration in selected third-countries" - AMIF-2017-AG-INFO (14/12/2017)
Call for Tenders: "Open microbusiness models for innovation in European family-owned heritage houses" - EAC/50/2017 (14/12/2017)
Call for Tenders: "Study on the costs of compliance for the financial sector" - FISMA/2017/091/B (14/12/2017)
Call for Tenders: "Support for Social protection statistics" - ESTAT/F/2017/023 (14/12/2017)
Partner Search: Creative Europe - Culture - ARCHITECTURE REGION EUROPE (13/12/2017)
Εβδομαδιαία Επισκόπηση  
Εβδομαδιαία Επισκόπηση Τεύχος 531 04.-08.12.2017 (11/12/2017)
Εβδομαδιαία Επισκόπηση Τεύχος 530 27.11.-01.12.2017 (04/12/2017)
Εβδομαδιαία Επισκόπηση Τεύχος 529 20-24.11.2017 (29/11/2017)
Εβδομαδιαία Επισκόπηση Τεύχος 528 13-17.11.2017 (20/11/2017)
Εβδομαδιαία Επισκόπηση Τεύχος 527 06-10.11.2017 (13/11/2017)
 Ενημέρωση Χρηματοδοτούμενων Ευρωπαϊκών Προγραμμάτων 
Προκηρύξεις Προγραμμάτων - Calls for Proposals
Προκηρύξεις Συμβάσεων - Calls for Tenders
Προτάσεις Συνεργασίας - Partner Search
Πρόσκληση Δημοσιεύσεων - Call for Papers
Πρόσκληση Εκδήλωσης Ενδιαφέροντος - Call for Expression of Interest
Πρόσκληση Υποψηφίων - Call for Applicants
Call for Proposals: Innovative Medicines Initiative (IMI): "IMI Joint Undertaking 2 Call 13"- H2020-JTI-IMI2-2017-13-two-stage

Call for proposals

Innovative Medicines Initiative (IMI): “IMI Joint Undertaking 2 Call 13”

- H2020-JTI-IMI2-2017-13-two-stage

 

Objective and description


A new call for proposals has been published under the Innovative Medicines Initiative (IMI): “IMI Joint Undertaking 2 Call 13” - H2020-JTI-IMI2-2017-13-two-stage.

 

The Innovative Medicines Initiative (IMI) is a jointly funded partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

 

The IMI 2 Joint Undertaking (IMI2 JU) aims to support research related to the future of medicine should in areas where societal, public health and biomedical industry competitiveness goals are aligned and require the pooling of resources and greater collaboration between the public and private sectors, with the involvement of small and medium sized enterprises (SMEs). The areas should be of public health interest, as identified by the World Health Organisation (WHO) report on priority medicines for Europe and the World.

 

The call for proposals refers to the following topics:

1.     IMI2-2017-13-01: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches (RIA)

2.     IMI2-2017-13-02: Genome-Environment Interactions in Inflammatory Skin Disease(RIA)

3.     IMI2-2017-13-03: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use(RIA)

4.     IMI2-2017-13-04: Mitochondrial Dysfunction in Neurodegeneration(RIA)

5.     IMI2-2017-13-05: Support and coordination action for the projects of the Neurodegeneration area of the Innovative Medicines Initiative (CSA)

6.     IMI2-2017-13-06: A sustainable European induced pluripotent stem cell platform(RIA)

7.     IMI2-2017-13-07: Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice(RIA)

8.     IMI2-2017-13-08: Human Tumour Microenvironment Immunoprofiling(RIA)

9.     IMI2-2017-13-09: ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now(RIA)

10.  IMI2-2017-13-10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system(RIA)

11.  IMI2-2017-13-11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease(RIA)

12.  Pilot programme on a Clinical Compound Bank for Repurposing:

·         IMI2-2017-13-12: Pilot programme on a Clinical Compound Bank for Repurposing: Cardiovascular diseases and diabetes(RIA)

·         IMI2-2017-13-13: Pilot programme on a Clinical Compound Bank for Repurposing: Respiratory diseases(RIA)

·         IMI2-2017-13-14: Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases(RIA)

·         IMI2-2017-13-15: Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases(RIA)

Eligible applicants


Only the following participants shall be eligible for funding from the Innovative Medicines Initiative 2 Joint Undertaking:

1.     legal entities established in a Member State or an associated country, or created under Union law and which fall within one of the following categories:

·         micro, small and medium-sized enterprises and other companies with an annual turnover of EUR 500 million or less, the latter not being affiliated entities of companies with an annual turnover of more than 500 million; the definition of ‘affiliated entities’ within the meaning of Article 2(1)(2) of Regulation (EU) No 1290/2013 shall apply mutatis mutandis;

·         secondary and higher education establishments;

·         non-profit organisations, including those carrying out research or technological development as one of their main objectives or those that are patient organisations.

2.     the Joint Research Centre

3.     international European interest organisations

 

Part C of the General Annexes to the Horizon 2020 – Work Programme 2016 – 2017 apply mutatis mutandis for the actions covered by this Call for proposals.

In addition, under all two-stage submission procedures the following additional condition applies: The participants from EFPIA constituent entities and affiliated entities and other Associated Partners which are pre-defined in the topics - under the section ‘Industry consortium’ – of a call for proposals do not apply at the stage 1 of the call. The applicant consortium selected from the stage 1 of the Call for Proposals is merged at the stage 2 with the EFPIA constituent entities or their affiliated entities and other Associated Partners.

Budget and duration


The total indicative budget for “Innovative Medicines Initiative Call 13” - H2020-JTI-IMI2-2017-13-two-stage is EUR 106 629 000 from EFPIA companies and IMI2 JU Associated Partners and EUR 116 421 000 from IMI2 JU.

The budget for each topic is distributed as follows:

1.     IMI2-2017-13-01: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches (RIA)

The indicative EFPIA in-kind contribution is EUR 6 000 000. The financial contribution from IMI2 JU is a maximum of EUR 6 700 000. Due to the global nature of the participating industry partners it is anticipated that some elements of the contributions will be non- EU/H2020 Associated Countries in-kind contributions. The indicative duration of the action is 60 months.

2.     IMI2-2017-13-02: Genome-Environment Interactions in Inflammatory Skin Disease(RIA)

The indicative industry in-kind contribution is EUR 8 300 000. The financial contribution from IMI2 JU is a maximum of EUR 10 500 000. Due to the global nature of the participating industry partners it is anticipated that some elements of the contributions will be non-EU/H2020 Associated Countries in-kind contributions. The indicative duration of the action is 60 months.

3.     IMI2-2017-13-03: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use(RIA)

The indicative in-kind and financial contribution from EFPIA partners and IMI2 JU Associated Partners is EUR 6 800 000. This contribution comprises an indicative EFPIA in-kind contribution of EUR 1 945 000 and an indicative IMI2 JU Associated Partners in-kind and financial contribution of EUR 4 855 000, of which EUR 3 805 000 financial contribution to the beneficiaries receiving JU funding in the selected action. The financial contribution from IMI2 JU is a maximum of EUR 6 800 000. The total financial contribution available to applicants for proposed activities in relation to the objectives of this action is therefore EUR 10 605 000. The indicative duration of the action is 48 months.

4.     IMI2-2017-13-04: Mitochondrial Dysfunction in Neurodegeneration(RIA)

The indicative industry in-kind contribution is EUR 3 288 000. This contribution comprises an indicative EFPIA in-kind contribution of EUR 3 120 000 and an indicative IMI2 JU Associated Partners in kind contribution of EUR 168 000. Due to the global nature of the participating industry partners, it is anticipated that some elements of the contributions will be non-EU/H2020 Associated Countries in-kind contributions. The financial contribution from IMI2 JU is a maximum of EUR 4 500 000. The indicative duration of the action is 36 months.

5.     IMI2-2017-13-05: Support and coordination action for the projects of the Neurodegeneration area of the Innovative Medicines Initiative (CSA)

The indicative industry in-kind contribution is EUR 1 200 000. This contribution comprises an indicative EFPIA in-kind contribution of EUR 1 056 000 and an indicative IMI2 JU Associated Partner in kind contribution of EUR 144 000. Due to the global nature of the participating industry partners, it is anticipated that some elements of the contributions will be non-EU/H2020 Associated Countries in-kind contributions. The financial contribution from IMI2 JU is a maximum of EUR 1 200 000. The indicative duration of the action is 36 months.

6.     IMI2-2017-13-06: A sustainable European induced pluripotent stem cell platform(RIA)

The indicative EFPIA in-kind contribution is EUR 4 000 000. Due to the global nature of the participating industry partners, it is anticipated that some elements of the contributions will be non-EU/H2020 Associated Countries in-kind contributions. The financial contribution from IMI2 JU is a maximum of EUR 4 600 000. The indicative duration of the action is 36 months.

7.     IMI2-2017-13-07: Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice(RIA)

The indicative EFPIA in-kind contribution is EUR 24 700 000. Due to the global nature of the participating industry partners it is anticipated that some elements of the contributions will be non-EU in-kind contribution. The financial contribution from IMI2 JU is a maximum of EUR 25 500 000. The indicative duration of the action is 60 months.

8.     IMI2-2017-13-08: Human Tumour Microenvironment Immunoprofiling(RIA)

The indicative EFPIA contribution is EUR 16 350 000. This indicative figure includes EUR 6 300 000 as in-kind contribution and EUR 10 050 000 as financial contribution to the beneficiaries receiving JU funding in the selected action. Due to the global nature of the participating industry partners, it is anticipated that some elements of the contributions will be non-EU/H2020 Associated Countries in-kind contribution. The financial contribution from IMI2 JU is a maximum of EUR 17 830 000. The indicative duration of the action is 60 months.

9.     IMI2-2017-13-09: ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now(RIA)

The indicative EFPIA in-kind contribution is EUR 13 500 000. Due to the global nature of the participating industry partners it is anticipated that some elements of the contributions will be non-EU in-kind contribution. The financial contribution from IMI2 JU is a maximum of EUR 15 300 000. The duration of the action is 60 months.

10.  IMI2-2017-13-10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system(RIA)

The indicative EFPIA in-kind contribution is EUR 4 331 000. Due to the nature of the participating industry partners it is anticipated that some elements of the contributions will be non-EU/H2020 Associated Countries in-kind contributions. The financial contribution from IMI2 JU is a maximum of EUR 5 331 000. The indicative duration of the action is 36 months.

11.  IMI2-2017-13-11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease(RIA)

The indicative EFPIA in-kind contribution is EUR 14 000 000. Due to the global nature of the participating industry partners, it is anticipated that some elements of the contributions will be non-EU/H2020 Associated Countries in-kind contributions. The financial contribution from IMI2 JU is a maximum of EUR 14 000 000. The indicative duration of the action is 60 months.

12.  Pilot programme on a Clinical Compound Bank for Repurposing:

·         IMI2-2017-13-12: Pilot programme on a Clinical Compound Bank for Repurposing: Cardiovascular diseases and diabetes(RIA)

·         IMI2-2017-13-13: Pilot programme on a Clinical Compound Bank for Repurposing: Respiratory diseases(RIA)

·         IMI2-2017-13-14: Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases(RIA)

·         IMI2-2017-13-15: Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases(RIA)

The indicative EFPIA in-kind contribution is EUR 4 160 000. Due to the global nature of the participating industry partners, it is anticipated that some elements of the contributions will be non-EU/H2020 Associated Countries in-kind contributions. The financial contribution from IMI2 JU is a maximum of EUR 4 160 000. Under each topic, the maximum IMI2 JU contribution is EUR 1 000 000 per clinical study and an additional EUR 40 000 if a preceding preclinical study is proposed. The indicative duration of the action is 48 months.

 

Deadline for proposals’ submission


The deadline of this call is 28 February 2018, 17:00 (Brussels local time) for the first stage, and 6 September 2018, 17:00 (Brussels local time) for the second stage.


Applicants must submit their proposal electronically, following the link on the submission service.

 

Further information


Please find attached the call documents as well as a presentation on IMI2 held in Brussels on 7 November 2017 and the EOC corresponding note.

 

MI will hold webinars on IMI2 – Call 13 from 27 November to 15 December inclusive (http://www.imi.europa.eu/news-events/events/webinars-imi2-call-13).

 

All webinars on the Call topics will feature a presentation by the EFPIA topic coordinator and time for questions and answers. The webinars represent an excellent opportunity to learn more about the Call topics, interact directly with the topic coordinators, and get in touch with potential project partners.

 

More information: https://tinyurl.com/y9aff5ls

 

Kind regards,

 

Flora Stavropoulou
Intern

European Office of Cyprus

Rue du Luxembourg 3, 2nd floor

B-1000, Brussels

Tel/Fax: +32 (0) 2 280 22 85

E-mail: eoc.brussels2@ucy.ac.cy

 

PLEASE NOTE THAT THE GREEK TRANSLATION IS PROVIDED AT REQUEST OF ANY INTERESTED MEMBER (based on the decision of 22.12.2016 of the EOC Administrative Council).





^ Αρχή Σελίδας